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Abstract
Maspin (mammary serine protease inhibitor), is a member of the serine protease inhibitor/non-inhibitor superfamily.
Its expression is down-regulated in breast, prostate, gastric and melanoma cancers but over-expressed in pancreatic,
gallbladder, colorectal, and thyroid cancers suggesting that maspin may play different activities in different cell
types. However, maspin expression seems to be correlated with better prognosis in prostate, bladder, lung, gastric,
colorectal, head and neck, thyroid and melanoma cancer. In breast and ovarian cancer maspin significance is
associated with its subcellular localization: nucleus maspin expression correlates with a good prognosis, whilst in
pancreatic cancer it predicts a poor prognosis. Since tumor metastasis requires the detachment and invasion of
tumor cells through the basement membrane and stroma, a selectively increased adhesion by the presence of
maspin may contribute to the inhibition of tumor metastasis. Furthermore the different position of maspin inside
the cell or its epigenetic modifications may explain the different behavior of the expression of maspin between
tumors. The expression of maspin might be useful as a prognostic and possibly predictive factor for patients with
particular types of cancer and data can guide physicians in selecting therapy. Its expression in circulating tumor
cells especially in breast cancer, could be also useful in clinical practice along with other factors, such as age,
comorbidities, blood examinations in order to select the best therapy to be carried out. Focusing on the
malignancies in which maspin showed a positive prognostic value, therapeutic approaches studied so far aimed to
re-activate a dormant tumor suppressor gene by designed transcription factors, to hit the system that inhibits the
expression of maspin, to identify natural substances that can determine the activation and the expression of maspin
or possible “molecules binds” to introduce maspin in cancer cell and gene therapy capable of up-regulating the
maspin in an attempt to reduce primarily the risk of metastasis.
Further studies in these directions are necessary to better define the therapeutic implication of maspin.
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Introduction
Maspin (mammary serine protease inhibitor), is a member
of the serine protease inhibitor/non-inhibitor superfamily
(serpin), like plasminogen activator inhibitors 1 and 2 and
α1-antitrypsin. Maspin gene is located on chromosome
18q21.3–q23 and it was identified for the first time in 1994.
Maspin expression is down-regulated in breast, prostate,
gastric and melanoma cancers but over-expressed in
pancreatic, gallbladder, colorectal, and thyroid cancers
suggesting that maspin may play different activity in
different cell types. These conflicting observations might be
explained by distinct subcellular localization of maspin in
cancer cells (cytoplasmic, nuclear or both cytoplasmic-
nuclear expression); by interactions with extracellular
matrix and its structure and epigenetic modifications [1-4].
A characteristic feature of serpin structure, is a
reactive center loop (RCL), a peptide stretch that is
located 9–15 residues amino-terminal to the reactive
site peptide bond. RCL allows the reactive site to present
an optimal configuration for binding, and subsequent
inhibiting target protease.
The conformational change is known as the “stressed-to
-relaxed” transition. Maspin, however, contains a relatively
short, divergent, not highly conserved, hydrophobic RCL
not capable of undergoing this transition. Collectively,
* Correspondence: r.berardi@univpm.it
Medical Oncology Unit, Università Politecnica delle Marche, Azienda
Ospedaliero-Universitaria Ospedali Riuniti Umberto I, GM Lancisi, G Salesi di
Ancona, Via Conca, Ancona 71-60126, Italy
© 2013 Berardi et al.; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly cited.
Berardi et al. Clinical and Translational Medicine 2013, 2:8
http://www.clintransmed.com/content/2/1/8
these properties place maspin into the non-inhibitory
category of the large serpin superfamily and shift the
focus away from attempting to identify a target pro-
tease as explanation for the biological activities of
maspin (Figure 1) [5-7].
Another interesting aspect of Maspin pertains to the G
α-helix (G-helix), an internal salt bridge or the P1 position
of the reactive center loop. The Maspin G-helix is capable
of an “open and closed” conformational change inducing
redistribution of charged residues within the molecule.
An intact G-helix is absolutely required for the effect of
maspin on cell migration, and the effect of the maspin
protein can be mimicked by a short peptide corresponding
to this structural element. Maspin and the G-helix in
isolation are reliant on α1 integrins for their effects on cell
migration [8].
Furthermore the action of maspin on cell migration
needed a 15-mer G-helix peptide right direct binding to
the β1 integrin subunit resulting in the inactivation of β1
integrins (Figure 2) [9-11].
In fact several studies showed that Maspin elicits
changes in the expression of proteins associated with the
actin cytoskeleton that predict a less motile and
invasive phenotype and reduced metastatic spread.
Moreover, RCL appears to mediate binding to a cell
surface receptor that promotes cell adhesion to type I
collagen and fibronectin [12,13].
To confirm this maspin action time-lapse video
microscopic studies showed that recombinant maspin
dramatically also inhibited the lamellopodia extension
and vectorial translation [14].
Since tumor metastasis requires the detachment and
invasion of tumor cells through the basement membrane
and stroma, selectively increased adhesion by the
presence of maspin may contribute to the inhibition of
tumor metastasis (Figure 3) [15-17].
During the process of metastasis, there are consistent
changes in gene expression. Studies of genes that are
reduced or silenced have yielded surprising insights into
in vivo mechanisms of regulating tumor metastasis. This
review describes a tumor suppressor gene, Maspin,
which is often silenced in cancer cells and exhibits
suppressing activity against tumor growth and metasta-
sis. Maspin has been shown to be involved in processes
that are important to both tumor growth and metastasis
such as cell invasion, angiogenesis, and more recently
apoptosis. Hence, many efforts have been devoted to
deciphering the molecular mechanism of maspin. While
some insights have come from the protease inhibitory
effect of maspin, more perceptive results on how maspin
may function in suppressing tumor metastasis have come
from studies of gene manipulation, protein interactions
and global protein profiling [18].
Recent evidence indicates, however, that nuclear
localization of maspin in cancer cells is necessary for its
tumor suppressor activity and nuclear-localized maspin
binds to chromatin are required to effectively prevent
cells from metastasizing [19].
About subcellular distribution, Maspin is predominantly
cytoplasmic but it also localizes to other cellular compart-
ments and is secreted. Secreted Maspin could bind to
Figure 1 The x-ray crystal structure of maspin.
Figure 2 Maspin three-dimensional structure.
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extracellular matrix components. Alternatively, it is pos-
sible that maspin exerts its role only in the nucleus at the
level of gene or chromatin regulation and thus indirectly
affects the cell-matrix interaction or differentiation state
and is released only as a consequence of cell damage or
necrosis [20-27].
It has recently established that maspin is epigenetically
regulated in tissue-specific way. Epigenetic changes of
maspin expression involve cytosine methylation, histone,
deacetylation, and chromatin accessibility causing loss of
gene function [28-30].
Several studies showed that over-expression of maspin
in gastric, pancreatic, and ovarian cancers results from
promoter CpG demethylation. This clearly indicates that
both methylation and demethylation of maspin pro-
moter could regulate maspin gene expression and could
guide the interpretation of overexpression/down regula-
tion associated with negative prognosis. The promoter
methylation of the maspin gene leads to gene silencing
in several tumors such as breast, thyroid, skin, and colon
cancer and it has been recognized as one of the most
frequent mechanisms causing loss of gene function. It is
noteworthy that in somatic tissues, the majority of CpG
islands are methylated, and tumor cells have global
DNA hypomethylation compared with their normal
counterparts. Hypomethylation is involved in the pro-
gression from the premalignant to a fully developed
malignancy and leads to activation of genes important
for cancer development [31].
Breast cancer
Maspin is the only pro-apoptotic serpin implicated in
apoptosis regulation in breast cancer. The intracellular
maspin can translocate to the mitochondria to induce
cytochrome c release and caspase activation or modulate
expression of Bcl-2 family members [32-40].
In order to confirm maspin tumor suppressor func-
tion, several authors investigated in vitro maspin expres-
sion in different tissue, from normal gland to metastatic
disease. Maspin expression appears to be reduced in
advanced stages of breast cancer. In fact, a significant
stepwise decrease in maspin expression (and in vascular
endothelial growth factor (VEGF) expression) occurred
in the sequence DCIS (Ductal Carcinoma In Situ)- inva-
sive cancer – brain-lymph-node-bone metastasis experi-
ments. Myoepithelium, normal breast and fibrocystic
change showed a strong maspin expression [41-43].
Even if Maspin absence emerges as an indicator of
tumor progression and metastatic potential, recent
studies showed that maspin expression was correlated
with an aggressive phenotype in the breast cancer and
with poor prognosis. Three hypothesis were thought
for the aberrant expression of maspin in breast cancer
cells: maspin gene alteration with loss of activity; a
high intracellular density of maspin resulting in auto-
inhibition of its function; myoepithelial cell differentiation
in cancer cells could contribute to more aggressive
phenotype. It is also important to investigate the
different subcellular maspin expression. In fact
nuclear staining was demonstrated to be significantly
associated with better a prognosis than cytoplasmic
staining [44,45].
Umekita et al. and Kim et al. examined, 92 and 192
invasive ductal carcinomas respectively. They reported
that maspin expression was frequently observed in
invasive ductal carcinoma with an aggressive phenotype
Figure 3 Mechanism of maspin function in most of human cancer.
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(i.e. high histological grade), and it was a strong indicator
of a poor prognosis [46,47].
Conversely, in order to define the significance of
subcellular maspin location, Mohsin et al. performed a
preliminary study assessing the associations of maspin
with other established prognostic factors in invasive
breast cancer. In a series of 1068 breast cancer maspin
nuclear staining was significantly associated with good
prognostic factors rather than cytoplasmic staining [48].
Furthermore the prognostic role of maspin was
investigated by Umekita et al. and Lee et al. They
examined maspin and p53 expression in 168 and 80
patients with invasive ductal carcinoma, respectively.
Large tumor size, high histologic grade, positive p53
status, negative estrogen receptor or progesterone
receptor status and poor prognosis were correlated
with maspin expression [49-51].
Stark et al. and Maas et al., instead, investigated the
potential correlations between maspin expression in
primary tumor and in the metastatic sites. They showed
that maspin expression is reduced in primary tumors
and again decreased in metastasis [52,53].
This finding adds maspin to the list of metastasis
suppressor genes potentially involved in the spread of
breast cancer metastases (Table 1).
Nevertheless, further investigations are needed to clar-
ify the real mechanism of the aberrant expression of
maspin in breast cancer, also in order to use it as a
prognostic marker in clinical practice.
Prostate cancer
In human prostate cancer, maspin expression consis-
tently appears to be down-regulated at the critical transi-
tion from non-invasive, low grade to high grade prostate
cancer. In particular, the loss of basolateral maspin
expression in benign secretory cells, the dramatically
up-regulation in High Grade Prostatic Intraepithelial
Neoplasia and the progressively decrease in invasive
Table 1 Maspin expression in breast cancer
Authors Year N. patients Maspin expression Clinical pathological features/prognosis
Umekita et al. 2003 92 (invasive
breast cancer)
18.5% positive maspin Positive maspin in invasive breast cancer and DCIS = large tumor size,




27 (atypical hyperplasia) 3.7% positive maspin
94 (usual hyperplasia) 0%positive maspin
Kim et al. 2003 192 (stage I-II
breast cancer)
34.4% positive maspin Positive maspin in all type of invasive breast cancer = high grade
36.4% positive maspin in
invasive ductal carcinoma
7.1% positive maspin in
invasive lobular carcinoma)
Mohsin at al. 2003 1068 (breast cancer) 35% positive cytoplasm Positive cytoplasmic maspin = negative ER and PgR, high Mib,
aneuploidy
96% positive nucleus Positive nuclear maspin = positive ER and PgR
Umekita et al. 2002 168 (breast cancer) 27.4% positive maspin Positive maspin = 17.4% Large tumor size, 43.4% high grade, 65.2%
negative ER and PgR, 43.4% positive p53 shorter PFS and OS
72.6% negative maspin Negative maspin = 9% large tumor size, 19.6% high grade 35.2%
negative ER and PgR 20,5% positive p53, better PFS and OS
Umekita et al. 2011 135 (triple negative
breast cancer)
85.9% positive maspin Positive maspin = 43.1% age ≤ 50 years, 80.2% high grade
14.1% negative maspin Negative maspin = 5.2% age ≤ 50 years, 42.1% high grade
Lee et al. 2006 80 (breast cancer) 31.3% positive maspin Positive maspin = 24% large tumor size, 52% high grade, 80% negative
PgR, Short PFS and OS
68.7% negative maspin Negative maspin = 7.2% large tumor size, 21.8% high grade, 41.8%
negative PgR, better PFS and OS




13% positive maspin in
brain metastasis
Maass et al. 2001 45 (breast cancer) 64% positive maspin 17.7% of patients develop metastasis = 75% negative maspin
36% negative maspin
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cancer are associated with maspin capability to reduce
tumor growth, osteolysis and angiogenesis. Furthermore,
there is an evidence that maspin inhibits prostate cancer-
induced bone matrix remodeling and induces prostate
cancer glandular redifferentiation [54-61].
Lovric et al. examined 34 biopsies of prostatic carcin-
oma. Maspin resulted expressed in the cytoplasm of basal
cells of normal prostatic glands, whilst normal luminal
cells were inconsistently weakly positive and it was
aberrant over-expressed in prostate cancer with a
predominance of nuclear presence [62].
On the other hand, Riddick et al. and Machtens et al.
analyzed gene expression and clinico-pathologic features
in 44 and 84 patients with prostate cancer, respectively.
Maspin expression was inversely correlated with the
Gleason score and positively correlated with lower
tumor stage, more differentiated grade and a lower p53
protein mutation [63,64].
Zou et al. investigated Maspin expression in 97
prostate tumor specimens showing that tumor cells that
exhibit histological response to neoadjuvant “hormonal
treatment” showed Maspin expression. These data
suggest that the androgen withdrawal may unmask
Maspin expression in prostate cancer, which frequently
lacks Maspin expression (Table 2) [65].
In conclusion, Maspin expression correlates with a
better prognosis and may serve as a biomarker for
prostate cancer cells responding to the androgen
ablation therapy.
Bladder cancer
Recent evidences seem to correlate a low maspin expres-
sion in bladder tumors to an increased tumor cell
growth both in vivo and in vitro. In particular, maspin
expression was preserved in superficial bladder cancers
but significantly decreased in invasive carcinomas.
Within the group of invasive cancers, the authors found
that maspin expression was associated with good
prognosis.
Recently, Lockett et al. showed the essential role of
maspin in epithelial homeostasis and that a sub-cellular
location of maspin seems to reflect a distinct tumor
progression pathway. In particular, the nuclear location
of maspin seems to be associated with lower histological
grade and longer recurrence free disease [65-79].
Acikalin et al. evaluated the clinical significance of
maspin in patients with T1 bladder cancer. They showed
that maspin expression was associated with a longer
time to recurrence and progression-free survival (PFS)
than maspin-negative group [80].
Furthermore Kramer et al. investigated the role of
maspin in transitional cell carcinoma of the bladder as
well as its prognostic impact. Specimens from 162 non-
muscle invasive bladder cancer patients treated by
transurethral resection were examined. They showed that
a low maspin protein expression was correlated with a
higher incidence of tumor progression and emphasized a
possible clinical role of this novel tumor suppressor gene
in transitional cell carcinoma of the bladder [81].
In another study, Friedrich et al. analyzed the expres-
sion patterns of maspin in 110 pTa/pT1 urothelial
carcinoma of the bladder and compared them with
microvessel density (MVD) evaluated by CD105 and
CD34. They found a decreased Maspin expression in a
large portion of pTa/pT1 bladder tumors and shorter
PFS with an increase of MVD in maspin negative
cancers [82].
Again, Sugimoto et al. evaluated maspin expression
in 65 series of bladder cancer. Maspin expression
was significantly correlated with the development of
muscle invasive bladder cancer. Their contradictory
results were explained by the fact that maspin could
contribute to bladder cancer development through
DNA methylation and histone deacetylation [83].
Another recent study, focused on the role of Maspin
in squamous cell carcinoma (SCC) and transitional cell
carcinoma (TCC) of urinary bladder.
In 134 bladder cancer patients, the relationship
between clinico-pathological features and Maspin was
examined and a high Maspin expression was found in
low grade and advanced stage. These results indicated
that Maspin expression might predict a better prog-
nosis for bladder carcinoma and it could play a role
in tumor progression [84].
Table 2 Maspin expression in prostate cancer
Authors Years N. patients Maspin expression Clinical features/prognosis
Lovric et al. 2010 34 prostate cancer 79% positive maspin with
nuclear expression
Riddick et al. 2005 44 prostate cancer Not found Positive maspin = lower Gleason score
Machtens et al. 2001 84 prostate cancer 58% positive maspin Positive maspin = OS: 78 months, PFS: 41 months, GIII-IV: 23%, N1/N2:
9% OS = 62 months, PFS = 26 months, GIII-IV = 48%, N1/N2 = 18%
18% negative maspin
Zou et al. 2002 97 prostate cancer 40.2% positive maspin Positive maspin = 91.7% partial response with neoadjuvant therapy
49.8% negative maspin
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Blandamura et al. evaluated, instead, maspin expression
in 111 bladder urothelial papillary neoplasms. Their
results showed that a strong expression of maspin is
related to a better outcome of papillary neoplasms and
this is apparently in contrast with the absence or reduced
maspin staining observed in the tumors of a lower histo-
logical grade and at pTa stage. This was probably due to
the fact that the lower grade papillary neoplasms do not
induce maspin activation, whereas high-grade neoplasms
exert maspin action in an attempt to restrict tumor
aggressiveness. (Table 3) [85].
In conclusion, further studies are needed to define the
role of maspin in clinical practice of bladder tumors.
Lung cancer
Several studies demonstrated that maspin inhibits the
survival pathway by influencing the response to cell
death in lung cancer cells [86].
Bircan et al. investigated maspin in 63 patients with
different histological lung carcinoma. The mean percentage
of maspin expression was significantly higher in squamous
cell carcinoma and adenocarcinoma, than in small cell lung
cancer (SCLC) [87].
Recently, in lung cancer, maspin biological functions
have been linked to its subcellular localization. Speci-
fically, a nuclear, opposed to a combined nuclear and
cytoplasmic localization has been associated with
increased survival in non-small cell lung cancer (NSCLC).
Lonardo et al., Frey et al., Woenckhaus et al. and Hirai
et al., examined 123 NSCLC, 80 adenocarcinoma, 487
tissue microarrays and 112 specimens, respectively. They
found that squamous cell carcinoma showed the highest
expression and almost exclusively a combined nuclear-
cytosolic stain in early stage. In contrast, nuclear maspin
alone, correlated with favorable clinico-pathologic features
and improved prognosis especially in adenocarcinoma
[88-90].
Recently our group showed that maspin expression, with
nuclear or cytoplasmic localization, together with smoking
history, represented prognostic factors in NSCLC. In par-
ticular a significant longer overall survival (OS) was seen in
patients with higher compared with lower expression of
nuclear maspin, and poorer OS was present in patients
with a higher intensity of cytoplasmic staining [91].
In another recent study, Wu et al. analysed the expres-
sion of maspin in NSCLC and its relationship to
vasculogenic mimicry (VM). A total of 160 specimens of
NSCLC were considered in this study. The loss of
maspin expression may contribute to the invasion and
metastasis of NSCLC and it has a positive relationship
to VM in NSCLC [92].
Again, Nakagawa et al., Katakuta et al. and Takanami
et al. investigated 210 consecutive patients with stage
I-IIIA NSCLC, 55 resected NSCLC patients and 181
patients with curatively resected NSCLC respectively.
Enhanced maspin expression was found a significant and
independent factor in predicting a favorable prognosis in
lung squamous cell carcinoma (Table 4) [93-95].
Ovarian cancer
An evidence that maspin can inhibit ovarian cancer
invasion has been shown in vitro, nevertheless the role
Table 3 Maspin expression in bladder cancer
Authors Years N. patients Maspin expression Clinical features/prognosis
Acikalin et al. 2012 68 (T1 bladder cancer) Not specified Positive maspin = longer PFS and less
recurrence
Negative maspin = shorter PFS and more
recurrence
Kramer at al. 2010 162 (pTa-pT1 bladder cancer) 75.9% positive maspin Positive maspin = PFS: 46 months
24.1% negative maspin Negative maspin = PFS: 18 months
Friedrich et al. 2004 110 (pTa-pT1 bladder cancer) 33.6% positive maspin Positive maspin = PFS: 29 months, MVD:
17.7(CD34) and 6.0 (CD105)per field
66.4%negative maspin Negative maspin = PFS: 23 months,
MVD = 21.7 (CD34) and 4.2 (CD105)per field
Sugimoto et al. 2004 65 (22 transurethral resection and
43 radical resection specimens)
18.2%positive maspin in transurethral
resection specimens
Positive maspin = progression from invasive
bladder cancer
51.2% positive maspin in radical
resection specimens
Nehad et al. 2010 134 (56 squamous cell carcinoma (scc)
and 78 transitional urinary bladder(tcc))
53.7% positive maspin
(42.8% scc and 61.5% tcc)
Positive maspin = 91.7% low grade
46.3% negative maspin Negative maspin = 54.8% high grade
Blandamura et al. 2008 66 (48 pTa e 18 pT1) 38% positive maspin 60.5% positive maspin have high grade
62% negative maspin 22.44% positive maspin have low grade
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Table 4 Maspin expression in lung cancer
Authors Years N. patients Maspin expression Clinical features/prognosis/predictive factors
Bircan et al. 2010 28 (squamous cell lung cancer) 89.3% positive maspin
18 (lung adenocarcinoma) 77.8% positive maspin
17 (small cell lung cancer) 52.9% positive maspin
Lonardo et al. 2005 46 (squamous cell lung cancer) 100% positive maspin Positive maspin = almost exclusively nuclear position
77 (lung adenocarcinoma) 93,5% positive maspin Positive nuclear maspin in squamous cell lung cancer = low grade, low proliferative rate,
absence of invasion, negative p53 vs nuclear-cytoplasmic position.
Frey et al. 2009 2009 80 (lung adenocarcinoma) 93.7% positive maspin
62.6% positive nucleus Positive nuclear maspin = 36.6% proliferative rate, Stage I OS: 87.7 ± 6.9 months, 42.5%
moderate and poor differantation, 25,5% p53+, 4.2% high VEGF
37.3% positive cytoplasm - nucleus Positive cytoplasmic maspin = 56.9%proliferative rate, Stage I OS: 58.7 ± 6.5 months, 71.4%
moderate and poor differantation,53.5% p53+, 39.2% high VEGF
Woenckhaus et al. 2007 487 (tissue microarrays) 72.3% positive maspin
65.3% positive nucleus Positive nuclear maspin = 63.9% squamous cancer, 16.9%
37.8% positive cytoplasm Positive cytoplasmic maspin = 78.2% squamous cancer, 6.8% adenocarcinoma adenocarcinoma
Hirai et al. 2005 112 (non-small cell lung cancer) 55.3%positive maspin Positive maspin = 77.8% positive cytoplasm Stage III and 36.2% positive cytoplasm Stage I
44.7% negative maspin
Berardi et al. 2010 439 (non-small cell lung cancer) 85.6% positive maspin Positive maspin = longer OS
22.8% positive nucleus Positive nuclear maspin = independent prognostic factor
44% positive cytoplasm Positive cytoplasmic maspin = especially smokers, lower OS than nuclear position
14.4% negative maspin Negative maspin = Lower OS
Wu et al. 2012 160 (non-small cell lung cancer) 48.1% positive maspin Positive maspin = lower vasculogenic mimicry and microvessel density, longer OS, low Stage,
low grade, low lymphnode metastasis
51.9% negative maspin Negative maspin = higher vasculogenic mimicry and microvessel density, lower OS, high
Stage, high grade, lymphnode metastasis
20 (normal tissue) 100% positive maspin
Nakagawa et al. 2006 210(non-small cell lung cancer) 73.7% positive maspin in squamous cancer Positive maspin = 70.1% 5-years OS
26.3%negative maspin in squamous cancer Negative maspin = 41.5% 5-years OS
Katakura et al. 2006 55 (non-small cell lung cancer) Not found Positive maspin = 67.7% 5-years OS
Negative maspin = 41.4% 5-years OS
Takanami et al. 2008 181 (non-small cell lung cancer) 40.8%positive maspin
65.7% positive maspin in squamous cancer Positive maspin in squamous cell lung cancer = 52.2% 5-years OS
34.3%negative maspin in squamous cancer Negative maspin in squamous cell lung cancer = 24% OS 5 years OS

















of maspin in ovarian cancer remains to be demonstrated.
However it seems that maspin expression level is low on
normal ovarian surface epithelium, while ovarian cancer
cell lines expressed high to low level of maspin
expression that is also correlated with shorter survival
in patients with epithelial ovarian cancer. Maspin
expression was predominantly located in the cytoplasm
and occasionally in the nucleus of epithelium and cancer
cells [96,97].
Klasa-Mazurkiewicz at al. examined 168 ovarian tissue
and found maspin level significantly higher in patients
with borderline tumors and early stages ovarian cancers
when compared with healthy tissues those with benign
and metastatic tumors. Over-expression of maspin was
found to correlate with early stage of disease in non-
serous subtypes of ovarian cancer and with a positive
response to chemotherapy. A statistically significant longer
PFS was observed in women with high as compared with
low expression of maspin. Again Moshira et al. examining
68 ovarian specimens: 7 normal tissue, 18 benign, 14 bor-
derline, 46 malignant epithelial ovarian neoplasm, detected
the same results about progression disease [98].
As well as in other tumor types, also in ovarian cancer
it is important its localization inside the cell in order to
define the role of maspin.
Sopel et al. and Solomon et al. studied 132 and 11
invasive epithelial ovarian carcinomas, respectively.
Cytoplasmatic maspin expression was correlated with
worse clinico-pathologic features and prognosis rather
than rare nuclear maspin expression [99,100].
Few studies compared maspin with VEGF in ovarian
carcinoma. In a recent study, over-expression of maspin,
VEGFC, and VEGFD was significantly associated with
unfavorable clinico-pathologic features and poor prog-
nosis in 60 ovarian carcinoma tissues. Similar results
were obtained by Sood et al. that assessed maspin
expression in 104 ovarian tissue specimens [101].
Bauerschlag et al. investigated the prognostic role of
maspin expression in 87 ovarian cancer specimens. There
was significant correlation between cytoplasmic maspin
expression and OS. Docetaxel- and paclitaxel-resistant
ovarian cell lines showed an even higher level of maspin
expression, suggesting an unfavorable role of cytoplasmic
maspin in ovarian cancer (Table 5) [102].
Colorectal cancer
Maspin has been investigated for its hypothetic implica-
tion in the cancerogenesis of colorectal cancer, for its
probable association with conventional histo-pathological
features and for its potential as an independent predictor
of survival and response to adjuvant chemotherapy.
Cao et al. investigated the relationship between chronic
inflammatory states and neoplasia in 125 specimens in-
cluded inflammatory bowel disease (IBD) with different
grade of dysplasia and also with invasive colorectal cancer.
Maspin was found paradoxically over-expressed in both
active IBD and colitis-associated dysplasia compared to
either inactive IBD or normal colonic mucosa, suggesting
a potential role in disease “flare” as well as neoplastic
progression [103].
Other recent studies demonstrated a sequential
decreased expression rate from adenoma to metastatic
colorectal carcinomas and an inverse correlation with
p53 and microvessel density [104-106].
Focusing on the clinico-pathologic features associated
with maspin, Umekita et al. studied expression of maspin
in colorectal adenocarcinomas from 104 patients and ob-
served that maspin was significantly correlated with the
depth of invasion, higher Dukes’ classification and high-
grade tumor budding. These results suggest that the ex-
pression of maspin may correlate with the aggressiveness
of colorectal adenocarcinomas [107].
On the other hand, Fung et al. examined 450 resected
colorectal cancer finding a stronger expression in right
than in left-sided tumors and a stronger expression in
high-grade tumors [108].
Regarding relationship between maspin, other bio-
marker and a possible target therapy, Gurzu at al. evalu-
ated maspin, p53 and other biomarker expression in 110
cases with colorectal cancer with the aim to correlate
maspin with angiogenesis and 5-Fluorouracil (5-FU)
therapy. They found a correlation with tumor stage and
microsatellite status. Therefore maspin nuclear expres-
sion, associated with p53 ones, might be used either to
select the high-risk microsatellite stable (MSS) colorectal
carcinomas diagnosed in Stage II or those MSI cases
which can respond to 5-FU [109].
In another recent study on 156 colorectal cases, signifi-
cant correlations between cytoplasmic expression and
high tumor grade and between nuclear expression, high
tumor budding and worse OS, were shown. These findings
suggest a compartment-dependent function of maspin in
colorectal cancer, which can be useful in identifying stage
II cases with a higher risk for fatal outcome with a possible
benefit from adjuvant chemotherapy [110].
Again Dietmaier et al. investigated nuclear maspin
expression in 172 primary stage III colon cancers
showing a significant treatment benefit from 5-FU
-based chemotherapy in patients with primary tumors
expressing Maspin in the nucleus. These data could
be useful, if confirmed in a prospective study, to
select patients to receive 5-FU treatment or an alter-
native (non-5-FU based) adjuvant therapy regime
(Table 6) [111].
Gastric cancer
In human gastric cancer the molecular aspect of car-
cinogenesis and progression remains elusive. Data are
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very few but it seems that maspin up-regulation may
cause a retarding cell proliferation [112].
Wang et al. investigated maspin expression in 113 gas-
tric cancer and compared it with clinical parameters,
MVD and Caspase-3 expression. Cancer less frequently
expressed maspin than normal mucosa and dysplasia.
Maspin expression showed a significantly negative correl-
ation with invasive depth, metastasis, Lauren’s and
Nakamura’s classification and MVD, but a positive correl-
ation with expression of Caspase-3 in gastric cancer [113].
In another recent study in 152 cases of gastric cancer, an
inverse relationship between maspin and p53 expression
was documented. Moreover maspin expression showed a
negative association with histologic grade, depth of
invasion, metastasis, and TNM stage. Interestingly, patients
with nuclear and cytoplasmic maspin expression presented
a longer survival than those with only cytoplasmic expres-
sion (Table 7) [114].
On the basis of all the above mentioned results,
Maspin expression could be considered as an effective
and objective marker to reveal biological behaviors of
gastric cancer and it could become an useful marker in
the future.
Pancreatic cancer
Unlike other malignant tumors, precancerous pancreatic
lesions and pancreatic cancer present up-regulation of
maspin gene expression, therefore maspin could be
Table 5 maspin expression in ovarian cancer
Authors Years N. patients Maspin expression Clinical features/prognosis
Klasa-Mazurkiewicz
et al.
2009 76 (ovarian cancer) 82.9% positive maspin Positive maspin = OS and PFS longer than maspin
negative tumor.
8(Krukemberg tumor) 87.2% positive maspin
10 (borderline) 90% borderline
42(benign tumor) 78.6% positive maspin
32(normal tissue) 53.1% positive maspin
Moshira et al. 2005 46(ovarian cancer)
14(borderline)
65.9% positive maspin = 69% positive
cytoplasm, 3.4% positive nucleus and
27.6% positive nucleus and cytoplasm
18(benign tumor) 57.1% positive maspin = 37.5% positive
cytoplasm and 62.5% positive nucleus
and cytoplasm
100% positive cytoplasm
Sopel et al. 2010 132 (ovarian cancer) 88.6% positive maspin
22% positive nucleus Positive nuclear maspin = low tumor grade,
less distant metastasis, low Figo stage, longer OS
12.9% positive cytoplasm Positive cytoplasmic maspin = high tumor
grade, probably distant metastasis, high Figo
stage, shorter OS
Solomon et al. 2006 118 (serous ovarian
cancer)
81.4% positive maspin
21.2% positive nucleus Positive nuclear maspin = lower VEGF and
COX-2, OS:1803 days
60.2% positive cytoplasm Positive cytoplasmic maspin = higher VEGF
and COX-2, OS:637 days
18.6% negative maspin Negative maspin = OS:1146 days
Bolat et al. 2008 60 (ovarian cancer) 88.3% positive cytoplasm Positive maspin = high VEGF, high grade, high
clinical stage, ascite, lymphnode methastasis
11.7% positive nucleus–cytoplasm
Sood et al. 2002 80(ovarian cancer) 71% positive maspin Positive maspin = shorter OS, 63.3% high grade
and 90% ascite
10 (borderline) 26.6% positive nucleus Positive nuclear maspin = longer OS
14 (benign tumor)
Bauerschlag et al. 2010 87 (ovarian cancer) Not found Positive maspin = OS: 28 months and platinum-therapy
resistance
Negative maspin = OS: 57 months
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considered a new factor associated with pancreatic can-
cer. Liu et al. and Maass at al. examined 102 and 29
specimens of pancreatic tissue and demonstrated that
more than 90% of cases of ductal adenocarcinoma as
well as all high-grade precancerous lesions (PanIN3)
were positive for maspin, and normal pancreatic ducts
and low-grade precancerous lesions were usually nega-
tive for maspin (Table 7) [115].
These data show that maspin may play an important
role in the carcinogenesis, tumor invasion, metastasis,
and angiogenesis of pancreatic cancer. Its relationship to
carcinoma of the pancreas opens a new angle to the
discussion on its function in cancer [116].
Gallbladder cancer
There are few published data focusing on maspin
expression in gallbladder cancer, but there is an evi-
dence of maspin implication in cholelithiasis-intestinal
metaplasia-dysplasia-carcinoma sequence and in the
early step of gallbladder cancerogenesis.
In a recent study on 69 patients with cholelithiasis
and 30 patients with gallbladder cancer without
cholelithiasis, a positive immunoreactivity for maspin
was significantly associated with the presence of intes-
tinal metaplasia in patients with cholelithiasis. These
data could support the assumption that intestinal
metaplasia of the gallbladder may predispose to gall-
bladder carcinoma [117].
Furthermore Kim et al. compared the pattern of
maspin expression in 101 early and advanced gallbladder
cancers. The positivity of maspin expression was found
almost in half of gallbladder cancers, whereas no maspin
was expressed in adenomas and normal mucosa of
gallbladder (Table 7) [118].
Head and neck cancer
Maspin seems to be an important prognostic factor also
in head and neck cancer. In particular some studies re-
vealed that the subcellular location seems to make the
difference. Nuclear expression is a positive prognostic
factor rather than cytoplasmic location [119,120].
Table 6 Maspin expression in colorectal cancer
Authors Years N. patients Maspin expression Clinical features/prognosis/predictive factors
Cao et al. 2005 25 (colorectal cancer
and IBD)
88%positive maspin
51 (active chronic IBD) 92% positive maspin
30 (inactive chronic IBD) 43% positive maspin
9(normal mucosa) 11% positive maspin
Song et al. 2002 66 (colorectal cancer) 75.5% positive maspin Positive maspin in colorectal cancer = 44.7% mutant
p53 expression, microvessel density = 181.1+/−54.2
24(adenoma) 24.5% negative maspin Negative maspin in colorectal cancer =microvessel
density = 256.1 +/75.4
91.7% positive maspin Positive maspin in adenoma = 0% mutant p53 expression
Jiang-tao et al. 2009 50 (colorectal cancer) 62% positive maspin Positive maspin in colorectal cancer = no association with positive
lymphnode, higher Duke’s stage or mutant p53 expression
20 (adenoma) 90% positive maspin
20 (normal mucosa) 95%positive maspin
Zheng et al. 2007 119 (colorectal cancer) 95% positive maspin Positive maspin in colorectal cancer = no liver metastasis = 89%
positive maspin
22 (adenoma) 93%positive maspin
118 (normal mucosa) 69%positive maspin
Umekita et al. 2006 104 (colorectal cancer) 66%positive maspin
(15% = T1-T2 and 78.5% = T3-T4)
Positive maspin = 44.2% absent tumor budding, 32.7%
Duke’s stage B
Fung et al. 2010 450 (colorectal cancer) 81%positive cytoplasm
80% positive nucleus
Positive maspin = right colon and high-grade tumor
Gurzu et al. 2012 101 (colorecatal cancer) 60% positive maspin Positive maspin = Stage II-III
Markl et al. 2010 156 (colorectal
cancer stage I-II)
48% positive nucleus Positive nuclear maspin = pT3 OS = 40 months
72% positive cytoplasm Positive cytoplasmic maspin = pT3 OS = 63 months
Dietmaier et al. 2006 172 (colorectal cancer) 44.4% negative nucleus Negative nuclear maspin = OS: 79.2%, OS after 5FU: 32.5%
55.6% positive nucleus Positive nuclear maspin = OS:66.6%, OS after 5FU: 71.7%
24.1% negative cytoplasm
75.9% positive cytoplasm
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Yoshizawa et al. and Iezzi et al. investigated the pos-
sible correlation between clinico-pathologic findings and
maspin expression in 54 and 89 oral squamous cell car-
cinoma, respectively. Maspin was associated with a bet-
ter survival rate, but a negative correlation with type
of invasion, T-stage, lymph-node metastasis and dif-
ferentiation grade was found [121-123].
Furthermore the cytoplasmic localization was signifi-
cantly associated with a high risk of disease disseminat-
ing to neck lymph-nodes in 56 consecutive cases of oral
carcinoma and the nuclear expression was correlated
with lower loco-regional recurrence rate and a longer
disease-free survival after treatment in elderly patient
with laryngeal carcinoma (Table 8) [124,125].
In conclusion, maspin may represent an useful marker
to identify the potential for progression of head and
neck cancer, since lower immunoreactivity is associated
with larger tumors and a greater invasive potential.
Furthermore in head and neck cancer it is necessary
to clarify the mechanisms between maspin expression
and progression of tumor in order to apply to clinical
applications.
Thyroid cancer
Maspin expression was investigated also in thyroid
neoplasms originating in follicular cells. Some studies
showed that neither normal follicular cells nor stro-
mal cells expressed maspin. Papillary and follicular
Table 7 maspin expression in gastric, pancreatic and gallbladder cancer
Authors Years N. patients Maspin expression Clinical features/prognosis/predictive factors
Wang et al. 2004 113 (gastric cancer) 50.5% positive maspin Positive maspin = T4: 35.9%, metastasis: 34.3%,
subtype diffuse: 42.1%, undifferentiated: 40%
49.5% negative maspin Negative maspin = T4: 64.1%, metastasis: 65.7%, s
ubtype diffuse: 57.9%, undifferentiated: 60%
Lee et al. 2008 152 (gastric cancer) 71.7% positive maspin
29.3% negative maspin Negative maspin = undifferentiated, high stage,
metastasis and invasion depth, positive p53
Liu et al. 2012 102 (pancreatic cancer) 98% positive maspin
Maas et al. 2001 24 (pancreatic cancer) 96% positive maspin
5 (PanIn3) 100% positive maspin
Maesawa 2006 69 (cholelithiasis) 14% positive maspin
14 (cholelitiasis + intestinal metaplasia) 64%positive maspin
Kim et al. 2012 101 (gallbladder cancer) 59.4% positive maspin
25(adenoma) 100% negative maspin
10 (normal gallbladder) 100%negative maspin
Table 8 maspin expression in head and neck cancers
Authors Year N. patients Maspin expression Clinical pathological features/prognosis
Yoshizawa et al. 2011 54 (OSCC) 64.8% positive maspin Positive maspin = 77.8% OS
35.2% negative maspin Negative maspin = 29.4% OS
Yoshizawa et al. 2009 71 (OSCC) 64.8% positive maspin Positive maspin = 100% low grade, 93.3% no
lymphnode metastasis, better OS
Iezzi et al. 2007 89 (OSCC) Not found Positive maspin = low grade, negative lymphnode,
high stage(?)
Marioni et al. 2008 56 (OSCC) 58.9% positive maspin
5.3 % positive nucleus
1.8% positive cytoplasm-nucleus
51.8% positive cytoplasm Positive cytoplasmic maspin = 61% pN0 and 33% pN+
41.1% negative maspin
Marioni et al. 2011 68 (laryngeal cancer) Not found Positive nucleus = 22.7% lower recurrence and PFS:
44.5 ± 27.5 months
Positive cytoplasm and cytoplasm-nucleus = 44.6%
longer recurrence and PFS: 34 ± 27.5 months
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carcinomas expressed maspin in significantly higher
incidence than those with pure papillary or follicular
patterns. These findings indicate that maspin expres-
sion is directly associated with prognosis in this
setting [126].
Boltze et al. and Tahany et al. detected maspin in
230 and 63 different histological thyroid tissue,
respectively, showing that its expression was typical of
papillary thyroid tumor, it was associated with tumor
multicentricity, vascular and lymphatic invasion, as
well as lymph-node metastasis and it was weakly
expressed in follicular cancer and absent in normal
tissue and in undifferentiated cancers. Maspin
expression is a special feature of papillary thyroid
carcinomas; promotor methylation-caused maspin
repression plays a major role in gene balance and in
the process of tumor determination. Therefore
maspin could possibly act as a clinically relevant
inhibitor of tumor progression, preventing local inva-
siveness and further systemic progression of papillary
thyroid carcinomas [127,128].
Data regarding the relation between maspin expression
and clinico-pathological parameters need to be further
confirmed on a larger scale with a longer follow up of
patients in order to evaluate its relationship with clinical
outcome including OS, disease free survival as well as
tumor recurrence (Table 9) [129].
Melanoma
In melanoma, Maspin was found to have a tumor-
suppressor function. Previous reports showed that early
hypermethylation of the Maspin promoter might play a
role in silencing Maspin. In particular Maspin promoter
activity was significantly increased after the thrombin
receptor protease activated receptor-1 (PAR-1) silencing,
suggesting that PAR1 negatively regulates Maspin at the
transcriptional level Maspin tumor-suppressor gene in
the acquisition of the metastatic melanoma phenotype
[130-133].
Wada et al. investigated maspin expression in five mel-
anoma cell lines, in a normal human epidermal melano-
cyte cell line, and in 80 surgically resected tumors. Their
results suggest that maspin expression in normal skin
melanocytes and melanocytic nevi may be repressed,
whereas maspin is aberrantly expressed in a subset of
melanoma cells by epigenetic modification. In particular
Chua et al. in 77 melanoma samples found maspin pres-
ence in the radial growth phase in melanoma, and a lost
maspin expression in the transition from the radial
growth phase to the vertical growth phase of melanoma
(Table 9) [134,135].
Future perspectives
The expression of maspin might be useful as a prognos-
tic and possibly predictive factor for patients with
particular types of cancer and data can guide physicians
in selecting therapy. Its expression in circulating tumor
cells especially in breast cancer, could be also useful in
clinical practice along with other factors, such as age,
comorbidities, blood examinations in order to select the
best therapy to be carried out.
Detecting maspin mRNA amplification by RT-PCR,
several authors, as mentioned above, showed maspin in
normal breast epithelial cells and in primary and meta-
static breast cells, but not in the peripheral blood of
healthy donors. Furthermore, they found the presence of
circulating maspin-positive cells, potentially neoplastic,
in the peripheral blood of patients with breast cancer
Table 9 Thyroid cancer and melanoma
Authors Years N. patients Maspin expression Clinical features/prognosis/predictive factors
Boltze et al. 2004 68 (papillary carcinomas) 70.5% positive maspin Positive maspin in papillary cancer = 2% p53+, 83% 110 months
OS, Recurrence free disease: 60 months
38 (follicular carcinomas) 100% negative maspin Negative maspin in follicular carcinomas = 80%p53+, 40%
110 months OS, Recurrence free disease :40months
Tahany et al. 2006 63(thyroid specimes)= 28.5%positive maspin Positive maspin = 72% papillary thyroid, 61,1% positive cytoplasm
and positive nucleus, 11.1 % positive nucleus and 27.8% positive
cytoplasm,
25 papillary carcinoma 71.5% negative maspin
Wada et al. 2004 45 (malignant melanoma) 12.5% positive maspin
87.5% negative maspin Negative maspin in melanoma = 83% trunk, 89% extremites, 89%
acral, 86% lentigo maligna melanoma, 100% nodular melanoma,
75% superficial spreading, 100% thickness 1.0-4.0 and >4 mm,
100% II-III-IV stage
Chua et al. 2009 77(malignant melanoma) 59.7% positive maspin Positive maspin = less microvessel density, 78% thin melanoma,
46% thick melanoma
35.1% negative maspin Negative maspin = high microvessel density, 22% thin melanomas,
54% thick melanoma
Berardi et al. Clinical and Translational Medicine 2013, 2:8 Page 12 of 19
http://www.clintransmed.com/content/2/1/8
undergoing conventional-dose chemotherapy. On the
basis of these observations, they assessed a possible
mobilizing effect of chemotherapy, delivered at standard
doses, on mammary cells of potential neoplastic origin.
Thus suggesting that the detection of circulating
breast cells could have prognostic significance, as it
was associated with a higher risk of early relapse or
disease progression for patients with limited or stage
IV disease, respectively. The results of these studies
should be interpreted with caution, and larger studies
with longer follow-up are required to definitely establish
the clinical usefulness of the test [136-139].
Moreover, maspin expression was found directly corre-
lated with treatment including carboplatin plus vinorelbine
combined with radiotherapy in primary head and neck
squamous cell carcinoma [140].
In some cases, the subcellular localization could predict
response to chemotherapy. In fact, nuclear maspin expres-
sion in patients with stage III colon cancer is associated
with response to adjuvant 5-FU-based chemotherapy and
could help to select patients whose tumors do not express
this molecule that may be candidates for an alternative
(non-5-FU-based) adjuvant therapy regimen.
Focusing on the malignancies in which maspin showed
a positive prognostic value, therapeutic approaches studied
so far aimed to re-activate a dormant tumor suppressor
gene by designed transcription factors, to hit the system
that inhibits the expression of maspin, to identify natural
substances that can determine the activation and the
expression of maspin or possible “molecules binds” to
introduce maspin in cancer cell and gene therapy capable
of up-regulating the maspin in an attempt to reduce
primarily the risk of metastasis.
Some authors hypothesized that artificial transcription
factors (ATFs), composed of modular zinc finger (ZF)
domains and designed to recognize specific sequences in
the promoter of a tumor suppressor, would result in a re-
expression of the endogenous gene silenced by epigenetic
mechanisms in aggressive tumor cells (e.g. in metastatic
breast cancer and in non-small cell lung cancer) and also
in up-regulation of E-cadherin. Reversal and modification
of the tumor suppressor epigenetic state can be achieved
by blocking DNA and histone methyltransferases as well
as histone deacetylases with different doses of ATFs and
chromatin remodeling drugs: the methyltransferase inhibi-
tor 5-aza-2’-deoxycytidine and the histone deacetylase
inhibitor suberoylanilide hydroxamic acid. It was found
that ATFs act in synergy with inhibitors in reactivating
endogenous maspin expression. The strongest synergy was
observed with the combination treatment ATF-126 + 5-
aza-2’-deoxycytidine + suberoylanilide hydroxamic acid.
While drugs can be used to achieve the inhibition of
these enzymes in an untargeted manner, the precise
mechanisms and the genetic cascades whereby these
drugs induce biological changes are currently not
completely understood and it seems to depend on
cell micro-environment. Furthermore, given that
tumor suppressors sustain anti-proliferative and anti-
metastatic functions, it is essential to target the native
tumor suppressor function in order to develop more
effective therapies.
Given the clinical relevance of maspin expression in a
variety of epithelial tumors (including breast, prostate,
lung and colon cancer), these studies describe a novel
approach to target multiple human tumors [141-148].
Recently, PAR-1 has been described to regulate the
gap junction protein Connexin 43 and the maspin tumor
suppressor gene to promote the metastatic melanoma
phenotype. Silencing PAR-1 results in decreased activation
of p38 MAPK, allowing for increased binding of c-Jun and
Ets-1 transcription factors to the maspin promoter.
Increased Maspin expression further inhibits cell inva-
sion, through decreased expression and activity of
MMP-2, as well as angiogenesis through decreased
VEGF expression [149].
An important role of IL-6TS in decreasing adhesion
and increasing motility and migration in prostate cancer,
along with its effect on the inhibition of maspin was also
found. Therefore, specific targeting IL-6TS in prostate
cancer patients, might represent an interesting way to
refine the currently available experimental anti-IL-6
therapies since sIL-6R and IL-6 are altered in patients
with a worse prognosis. This information may be helpful
to identify those patients who could benefit from the
anti-cytokine therapy [150].
Recent studies have investigated the use of maspin
as a therapeutic agent against cancer. In one study,
maspin was found to inhibit cancer growth and
metastasis in a breast cancer mouse model through a
maspin DNA-liposome therapy. Another study showed
the ability of maspin to induce apoptosis in tumor-specific
endothelial cells. Taken together, these studies demon-
strate the potential use of maspin as a viable anticancer
therapeutic agent [151]. Gene therapy focusing on the use
of adeno-associated virus (AAV, serotype 2) vector
encoding maspin in human prostate cancer was also
evaluated. Immunofluorescence double staining for
maspin protein and apoptosis in LNCaP tumors showed
that the percentage of apoptotic cells in AAV-maspin
-mediated maspin-expressing cells was significantly
high if compared with that in AAV-GFP-mediated
GFP-expressing cells. Moreover, significantly fewer
CD31-positive microvessels were observed in AAV-
maspin-treated tumors compared with the control
tumors. These therapeutic responses were highly
correlated to persistent maspin expression in tumors,
confirmed by Western blot analysis until at least 56
days after treatment. Furthermore AAV-mediated
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prolonged maspin expression efficiently suppresses
human prostate tumor growth in vivo by apoptosis
induction and inhibition of angiogenesis [152].
Focusing on natural substances, it has been showed
that curcumin, a hydrophobic polyphenol derived from
turmeric (the rhizome of the herb Curcuma longa), is
implicated in the inhibition of tumorigenesis with a
combination of anti-inflammatory, anti-oxidant, immu-
nomodulatory, pro-apoptotic, and anti-angiogenic prop-
erties via pleiotropic effects on genes and cell-signaling
pathways at multiple levels, including activation of tran-
scription factors, receptors, kinases, cytokines, enzymes
and growth factors.
When curcumin is combined with some cytotoxic drugs
or certain other diet-derived polyphenols, synergistic
effects have been demonstrated [153-155].
Curcumin has recently received a great deal of atten-
tion as a chemoprotective agent for the prevention of
colon and breast cancer and it may have clinical applica-
tion in the prevention of prostate cancer. Curcumin
Table 10 summary of maspin expression
Cancer Tumor progression normal to cancer Positive cytoplasm or
positive nucleus
Prognosis
Breast cancer Normal tissue: positive maspin Positive nucleus = better prognosis Positive maspin = better/worse
prognosis depending of localization
and of epigenetic modificationCancer tissue +/−
Cancer metastasis = negative maspin
Prostate cancer Normal tissue: Positive nucleus increased
in invasive cancer
Positive maspin = better prognosis
Negative maspin
HGPI: positive maspin
Invasive cancer = negative maspin
Bladder cancer Normal tissue: Positive nucleus = better prognosis Positive maspin = better prognosis
Positive maspin
Cancer tissue:
Negative maspin (T2→ T4 positive?)
Lung cancer Normal tissue: positive maspin Positive nucleus = better prognosis
vs nuclear and positive cytoplasm
Positive maspin = better prognosis
Lung cancer = less positive maspin
Ovarian cancer Normal tissue: Negative maspin Positive nucleus (rare) = better
prognosis
Positive maspin = better/worse
prognosis depending of localization
and of epigenetic modificationEarly stage
Ovarian cancer = positive maspin
Metastic cancer = less positive
Colorectal cancer Normal tissue: negative maspin Positive nucleus = worse prognosis Positive maspin = better prognosis,
positive response to 5FU therapy
Dysplasia and cancer = positive maspin Positive cytoplasm better prognosis
Gastric cancer Normal tissue: positive maspin Positive nucleus and positive
cytoplasm = better prognosis vs
only positive cytoplasm
Positive maspin = better prognosis
Cancer tissue: negative maspin
Pancreatic cancer Normal tissue: negative maspin Positive maspin = worse prognosis
Pan In1, Pan In2 = negative maspin
Pan In3 and cancer invasive tissue = positive maspin
Gallbladder cancer Normal tissue: dysplasia = negative maspin
intestinal metastasia and cancer = positive maspin
Head and neck
cancer
Positive nucleus = better prognosis Positive maspin = better prognosis
Thyroid cancer Normal tissue adenomas and follicular
carcinoma = negative maspin/+ papillary
carcinoma = positive maspin
Positive maspin = better prognosis
Anaplastic and poorly
differentiated = negative maspin
Melanoma
malignant
Normal tissue: positive maspin Positive nucleus = better prognosis Positive maspin = better prognosis
Melanoma = positive maspin
Metastatic melanoma = negative maspin
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down-regulates the androgen receptor gene not only at
the protein level but also in its transcriptional activity in
androgen-depended prostate cancer. The suppression of
androgen receptor transaction may affect the androgen
receptor regulated genes such as maspin and curcumin
increase the expression of maspin with dose and time
dependence.
The mechanism utilized by curcumin to up-regulate
maspin expression is unknown at this time. Nevertheless,
the up-regulation only occurs in cells that have wild-type
p53. This suggests that the activity of curcumin toward
maspin expression may be modulated through the p53
pathway. Two other examples of nutritional compounds
that have been reported to enhance tumor suppression
and inhibit metastasis through up-regulation of maspin
are abalone visceral extract and apple peel extract.
As in the case of curcumin, the cells treated with apple
peel extract displayed significant increases in the expression
of maspin [156-158].
Also resveratrol (trans-3, 49, 5-trihydroxystilbene), a
polyphenolic antioxidant found in peanuts, grapes and
red wine possesses significant health benefits. This com-
pound has shown beneficial effects in experimental cancer
models, where it suppresses the initiation, promotion and
progression of tumors Recent studies have implicated acti-
vation of the apoptotic pathway as a mechanism accoun-
ting for the antitumor benefits of resveratrol. For example,
resveratrol inhibits cell proliferation, induces apoptosis of
human prostate carcinoma and acute lymphoblastic
leukemia cells and increases maspin levels through Akt
pathway [159-163].
Conclusion
It is important to continue to search for the maspin in
different tumor types in order to better define its prognostic
significance, to refine the definition techniques of cellular
compartmentalization and to evaluate the possible thera-
peutic implications considering peculiarities of expression
of maspin in various cancers (Table 10).
The correlation between the expression of maspin and
clinical parameters is different depending on the type of
tumor. It is likely that the lack of standardization in
assessing the positivity of maspin subcellular level and the
need for more studies about it can explain and permit the
interpretation of differences. It would be more helpful to
evaluate the expression of maspin only as a positive
nucleus-cytoplasm to ensure greater uniformity of results.
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